Merck Sharp + Dohme Corp.

Other

Medshine Discovery Inc.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cgenetech (suzhou, China) Co., Ltd.

Cstone Pharmaceutical (suzhou) Co., Ltd.

Dongbao Purple Star (hangzhou) Biopharmaceutical Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Cgenetech Co., Ltd.

Msd R&d Co., Ltd.

Dongbao Purple Star Biopharmaceutical Co., Ltd

Shangdong Danhong Pharmaceutical Co., Ltd.

Qinghua Mao

Chun Sing Li

Shuhui Chen

Craig A Stump

Chengde Wu

Andrew John Cooke

Xu-Fang Zhang

Helen J Mitchell

Tao Yu

Mark E Fraley

Casey Cameron McComas

Ping Liu

Harold B Wood

Melody McWherter

Yi Li

Kathy Schirripa

Yi-Heng Chen

Swati P Mercer

Zhiqi Qi

Jian Li

Yi Bu Li

Jianming Bao

Douglas C Beshore

Dongfang Meng

Kerim Babaoglu

Zhen Gong

Keith P Moore

Dann Parker

Jane Yang Wu

Yong Huang

Lu Gan

Casey C Mccomas

Melody Mcwherter

Andrew J Cooke

Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically involved.

SGLT2/DPP4 inhibitor and application thereof

A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.

SGLTS/DPP4 inhibitor and application thereof

A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.

Glucoside derivative that acts as SGLT1 inhibitor and application thereof

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof. 

Coumarin-like cyclic compound as MEK inhibitor and use thereof

A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof. 

SGLTS inhibitor and application thereof

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TrKA kinase inhibitors, compositions and methods thereof

The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C. 

TrkA kinase inhibitors, compositions and methods thereof

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TRKA kinase inhibitors, compositions and methods thereof

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

Growing community of inventors

Shanghai, China

Qinghua Mao